These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35224108)

  • 1. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
    Akbari A; Rafiee M; Sathyapalan T; Sahebkar A
    J Diabetes Res; 2022; 2022():7520632. PubMed ID: 35224108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials.
    Li M; Zhang J; Yang G; Zhang J; Han M; Zhang Y; Liu Y
    Eur J Clin Pharmacol; 2023 Jun; 79(6):859-871. PubMed ID: 37097298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
    Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
    Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
    Luo Y; Bai R; Zhang W; Qin G
    Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
    Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
    Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
    Tanashat M; Manasrah A; Abouzid M
    Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
    Kanbay M; Tapoi L; Ureche C; Tanriover C; Cevik E; Demiray A; Afsar B; Cherney DZI; Covic A
    Int Urol Nephrol; 2022 Apr; 54(4):827-841. PubMed ID: 34273060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes.
    Hussain M; Elahi A; Hussain A; Iqbal J; Akhtar L; Majid A
    J Diabetes Res; 2021; 2021():9973862. PubMed ID: 34239940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.
    Deng R; Mei K; Song T; Huang J; Wu Y; Yu P; Yan Z; Liu X
    Front Endocrinol (Lausanne); 2024; 15():1289643. PubMed ID: 38348420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.
    Banerjee M; Pal R; Maisnam I; Chowdhury S; Mukhopadhyay S
    Diabetes Obes Metab; 2023 Sep; 25(9):2697-2703. PubMed ID: 37334516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis.
    Zhang L; Zhang F; Bai Y; Huang L; Zhong Y; Zhang X
    BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38238025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
    Matharu K; Chana K; Ferro CJ; Jones AM
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
    Fakhrolmobasheri M; Abhari AP; Manshaee B; Heidarpour M; Shafie D; Mohammadbeigi E; Mozafari AM; Mazaheri-Tehrani S
    Acta Diabetol; 2023 Feb; 60(2):191-202. PubMed ID: 36264350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
    McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E
    Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.